So proud of Dr. Cassandra Duarte for publishing this important study with the help of the Flatiron database! “Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia” haematologica.org/newsletter/v...

A US Senate committee endorsed maintaining the NIH's structure and increasing its funding by US$400 million, or about 1% go.nature.com/4mg193S

Congrats to my friend James DeGregori and his partner Mercedes Rincon and everyone involved on this beautiful study!

May the odds be ever in your favor. 4% payline at the NCI. www.cancer.gov/grants-train...

Orientation week is over and we are excited to have the new first years on rotation with us!

Outcomes of oral azacitidine and venetoclax in newly diagnosed AML. High responses in TP53 mut patients. www.vjhemonc.com/video/wmkfly...

Come check out our poster tonight! EHA2025

We made it!

Congratulations to Maria Amaya, MD, PhD, Assistant Professor of Medicine-Hematology (and CU HemeOnc Fellowship alumni) on being selected as one of the 2025 Translational Research Scholars. Each scholar receives research support over four years. #CUAnschutz #CUCancer

Four CU Cancer Center members have been tapped to serve as ambassadors for its four main scientific and clinical research programs ⬇️

An international study led by @cucancercenter.bsky.social has uncovered why a widely used treatment for acute myeloid #leukemia doesn’t work for everyone. The findings could help doctors better match patients with the therapies most likely to work for them. 💡

The crazy thing about firing all of these federal employees is that they tend to be underpaid, super hardworking, in it for the right reasons, idealistic people who could’ve worked in industry or pharma and made way more money but they truly believed in the mission and the good they were doing.

Unfortunately was not able to travel to EBMT but our poster can still be viewed virtually! We report on the first 7 #VEXAS patients who underwent allo-HCT on our prospective phase II trial. High rates of #GVHD and other inflammatory complications noted. @ Bhavisha Patel

jamanetwork.com/journals/jam... If part of the RIF is to let term contracts expire, they will completely decimate VA research in a matter of months, and researchers will be terminated with no severance.

All amazing women!

Good news for the week! (This Venezuelan federal worker is still making it work 😉) 1. We published our small retrospective study in CCUS vs tCCUS www.tandfonline.com/doi/full/10.... 2. Makenna from the lab presented her work to legislators and the public at the State capitol!

It’s been tough, not going to lie, but today we got a paper accepted and one of my PRAs’ visas got renewed and we will take any victories we can get! ❤️👩🏻‍🔬👩🏻‍🔬

CU Cancer Center's Deputy Associate Director of the Office of Engagement, Access, and Success, Curtis Henry, PhD, shares his thoughts with 9 News about the @acscan.bsky.social report that cancer is the second-leading cause of death for Black people ⬇️ www.9news.com/video/news/h...

If they fire staff that supports research, physicians and investigators will also be forced to leave…

“There’s going to be a missing age class of researchers that will reverberate for years.” scim.ag/3ERRLDo

CU Cancer Center member Manali Kamdar, MD, started to think about pivoting from her dream of being a dancer to a different profession after receiving care for a spinal injury. Now she is a highly recognized leading lymphoma researcher ⬇️

There’s no argument that should reassure anyone enough to go back to business as usual, because none of these actions are happening in isolation. The war on US science won’t end with a court order on indirects.

I believe that most of our society values science and scientists. We need to continue to communicate our findings and value to the public and advocate for increased research funding, especially for young investigators->they are the future.

Excited to share this commentary on a very interesting clinical trial for AML ashpublications.org/blood/articl... @bloodjournal.bsky.social

Fork in the road Q/A: Q: Can I take extended vacation while on administrative leave? A: You are most welcome to stay at home and relax or travel to your dream destination. Sure, let me go take an extended vacation while I leave Veretans hanging without care because we are already short-staffed.

Join us soon for a great session on mechanisms of therapy resistance in myeloid neoplasms. #ASH24

Amazing trainees presenting their amazing work! #ASH24

Fascinating talk by Shanshan Pei on a newly identified TFG-ROS1 fusion, that although rare it can cause CMML -> AML and can be targeted with ALK/ROS1 inhibitors. #AMLsm #ASH24

It’s ASH week! #ASHThrowback to 2019 Orlando plane ride with the amazing lab mate Shanshan Pei who is now a trailblazing independent investigator! He just came to visit and I look forward to his talk on Saturday. #AMLsm

Took me long but better late than never! This is our lab website and this Thanksgiving weekend I am grateful for everyone in the lab, they make science so fun! ladybug-triceratops-dpm6.squarespace.com

4-gene prognostic risk classifier (FLT3-ITD, KRAS, NRAS, and TP53) seems to successfully differentiate outcomes among patients with newly diagnosed AML treated with Aza/Ven than ELN 2017/2022 ashpublications.org/blood/articl...

Hello, #hematology community! ASH is now on BlueSky. We're here to share cutting-edge research and educational resources and connect global experts in blood diseases. Join us in advancing hematology together. Welcome, colleagues! #BloodSky #HemeSky #MedSky

How to make friends with a hematologist Chapter 1 1. Order a peripheral smear before they ask 2. Never get a CBC without a diff 3. Stop the heparin before you call for a HIT consult 4. NEVER order MTHFR 5. Order a reticulocyte count before you consult for anemia

Previous studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at Nature Genetics. www.nature.com/articles/s41...

Thanks to Flatironhealth we were able to analyze AML outcomes across the U.S. based on socioeconomic status. Lower SES pts are treated with more induction chemo and less novel therapies, likely contributing to worse survival. More at #ASH24 www.ajmc.com/view/real-wo...

Big day for our field! 🎉

Excited for #ASH2024! Come check out updates of our clinical trial with oral azacitidine and venetoclax in newly diagnosed AML. Great responses in this population!

Can’t miss! Registered :)